Gastroesophageal reflux disease
Conditions
Interventions
Experimental group:Xuanfei Zhike pilulas placebo combined with rabeprazole capsules
Control group:Xuanfei Zhike pilulas placebo combined with rabeprazole capsules
Sponsors
Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1 It meets the diagnostic criteria of western medicine reflux cough. 2 Conform to the diagnostic criteria of TCM liver-stomach stagnation-heat syndrome. 3Patients aged =18 years and =70 years old, regardless of gender. 4 Understand and agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1 Common diseases that can cause chronic cough, such as cough variant asthma, postnasal drip syndrome,Eosinophilic bronchitis, etc. 2 Other lung diseases that can cause chronic cough, such as lung cancer, chronic obstructive pulmonary disease,Tuberculosis, interstitial pneumonia, chronic bronchitis, etc. 3 Chronic cough caused by drugs, such as long-term use of angiotensin converting enzyme inhibitors (Angiotensinconvertingenzymeinhibitor, ACEI) drugs, etc. 4 Those with stomach diseases, such as gastric cancer, gastroduodenal ulcer, pyloric obstruction, Zoller-Ellison syndrome, etc. 5 Patients with esophageal organic diseases, such as Barrett's esophagus, drug-induced esophagitis, eosinophilicCellular esophagitis, etc. 6 Those with esophageal functional diseases, such as cardia achalasia, esophageal hiatal hernia, etc. 7 Severe primary diseases combined with important systems such as heart, brain, liver, kidney, blood and endocrine,not effectively controlled; and severe mental illness. 8 Exclusion of allergies: Those who are allergic to the western drug rabeprazole or any component of traditional Chinese medicine used in this study. 9 Women who are pregnant, pregnant or breastfeeding. 10 Those who have participated in or are participating in other clinical trials one month before enrollment, or must take them during the trial other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Symptom Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour esophageal impedance and pH monitoring;Electronic Gastroscopy;Cough Evaluation Test;Leicester cough questionnaire; | — |
Countries
China
Contacts
Public ContactZhou Bingduo
Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed